Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

Presentation AHA 2016

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

Presenter: Steven E. Nissen

November 15, 2016

News Conference News AHA 2016

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

Shelley Wood

November 13, 2016

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Michael O'Riordan

September 16, 2016

News Features

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

Michael O'Riordan

May 03, 2016

News Daily News

虚拟组织学血管内超声研究显示，他汀类药物会改变冠状动脉斑块的构成

Michael O'Riordan

April 14, 2016

News Daily News

Un Estudio Histología-IVUS Revela que el Tratamiento con Estatinas Altera la Composición de las Placas Coronarias

Michael O'Riordan

April 14, 2016

News Daily News

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Michael O'Riordan

April 14, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

Patrick Whitlow, ‘Giant of Interventional Cardiology,’ Dies at 65

Yael L. Maxwell

March 22, 2016

News Daily News

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

Michael O'Riordan

March 08, 2016

News Daily News

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Michael O'Riordan

March 08, 2016

News Daily News

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Michael O'Riordan

March 08, 2016

News Conference News ESC 2014

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

Todd Neale

September 02, 2014

Advertisement

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

GLAGOV Trial: Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound

No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

虚拟组织学血管内超声研究显示，他汀类药物会改变冠状动脉斑块的构成

Un Estudio Histología-IVUS Revela que el Tratamiento con Estatinas Altera la Composición de las Placas Coronarias

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Patrick Whitlow, ‘Giant of Interventional Cardiology,’ Dies at 65

备受争议的 LIGHT 试验现已发表，但未能证实 Contrave 的心血管风险

El Controvertido Ensayo LIGHT Ahora Publicado No Arroja Luz sobre los Riesgos CV de Contrave

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content